Product
Radiotherapy combined with TKI and Anti-PD-1 Antibody
1 clinical trial
1 indication
Indication
Stage IIIA Hepatocellular CarcinomaClinical trial
A Study to Evaluate the Effects of Radiotherapy Combined With Tyrosine Kinase Inhibitor (TKI) and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma With Portal Vein Tumor Thrombus(PVTT)Status: Recruiting, Estimated PCD: 2024-07-30